TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6832623

Group type: EXPERIMENTAL
Intervention: Cold pain (test stimulus: repeated one minute immersions of a hand into ice water, 20 minutes total)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (water at 37 degrees C)
Number of subjects: 9
Study: 30207587

Group type: EXPERIMENTAL
Intervention: Namilumab (20, 50, 80, and 150 mg via subcutaneous injection)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 28884242

Group type: EXPERIMENTAL
Intervention: Low-dose BoNT-A injections at the pretarsal (PT) portion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose BoNT-A injections at the preseptal (PS) portion
Number of subjects: 40
Study: 25778933

Group type: EXPERIMENTAL
Intervention: Full dose combination (paracetamol 1000 mg and ibuprofen 300 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Half dose combination (paracetamol 500 mg and ibuprofen 150 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Quarter dose combination (paracetamol 250 mg and ibuprofen 75 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All combination doses
Number of subjects: 159
Study: 23979345

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (BEE×1.1×1.3-1.5 kcal/kg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (BEE×1.1×1.1-1.3 kcal/kg/day)
Number of subjects: 50
Study: 21748479

Group type: EXPERIMENTAL
Intervention: Heavyweight polypropylene mesh (HWM) (105 g/m(2))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lightweight polypropylene mesh (LWM) (28 g/m(2))
Number of subjects: 32
Study: 18762940

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional standard procedure
Number of subjects: 100
Study: 16728451

Group type: EXPERIMENTAL
Intervention: L-NAME (20 mM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Local Cooling (34-24 degrees C) for 35 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BT + L-NAME
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP 10 microM)
Number of subjects: 8
Study: 11950112

Group type: EXPERIMENTAL
Intervention: Distraction condition (nurses used stimuli to divert infants' attention)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Typical care condition
Number of subjects: 90
Study: 10074644

Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microgram/kg/min increasing to 2 micrograms/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (dextrose 5%)
Number of subjects: 30
Study: 8834657

Group type: EXPERIMENTAL
Intervention: rhu-EPO treatment for 12 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: non-EPO group (clinical monitoring)
Number of subjects: 27

Group type: COMPARATOR
Intervention: HD group (haematocrit > or = 30% without rhu-EPO therapy)
Number of subjects: 27
Study: 2341262

Group type: EXPERIMENTAL
Intervention: Backrest position at 20 degrees
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Backrest position at 40 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat position (control)
Number of subjects: 30
Study: 7001038

Group type: EXPERIMENTAL
Intervention: Fixed drug combination of chloroquine and paracetamol (single dose)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Chloroquine and paracetamol given as separate tablets (extended over 3 days or longer)
Number of subjects: 154
Study: 6343259

Group type: EXPERIMENTAL
Intervention: 100 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mg once daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 mg once daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 200 mg once daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30974955

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ankle-Foot Orthoses (AFO)
Number of subjects: 85
Study: 29863586

Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 27846868

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study: 24647158

Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 180

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 180
Study: 22571394

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 10/20 mg/day
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 10/40 mg/day
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Benazepril 40 mg/day
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day
Number of subjects: 1013
Study: 19875481

Group type: EXPERIMENTAL
Intervention: IKK/NF-kappaB pathway activity measured by IkappaBbeta to p65 ratio
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IKK/NF-kappaB pathway activity
Number of subjects: 181
Study: 18803988

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine lozenge
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Emotional distress scores
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Craving scores
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 1144
Study: 16204708

Group type: EXPERIMENTAL
Intervention: Severe CAD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Left Ventricular Hypertrophy (LVH)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ischemia Score
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: LVH in patients with severe CAD
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diabetes in patients with severe CAD
Number of subjects: 103
Study: 12456454

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg IV
Number of subjects: 150

Group type: COMPARATOR
Intervention: normal saline IV (placebo)
Number of subjects: 150
Study: 10582974

Group type: EXPERIMENTAL
Intervention: High serum alpha‐tocopherol
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: High serum beta‐carotene
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > or = 160 mm Hg
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol > or = 7.0 mmol/L
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: Serum HDL cholesterol > or = 0.85 mmol/L
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol
Number of subjects: 28519
Study: 8618185

Group type: EXPERIMENTAL
Intervention: rHuEPO treatment with protein intake up to 3.1 gm/kg per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1753168

Group type: EXPERIMENTAL
Intervention: Coculture with passaged human tubal ampullary epithelial cells
Number of subjects: 32

Group type: COMPARATOR
Intervention: Culture medium alone
Number of subjects: 32
Study: 7085556

Group type: EXPERIMENTAL
Intervention: Aerosolized triamcinolone acetonide (200 micrograms inhalations, four times daily for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerosolized triamcinolone acetonide
Number of subjects: 30
Study: 31264757

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 4 mg once weekly
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 6 mg once weekly
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 6 mg once every 2 weeks
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Efpeglenatide 8 mg once every 2 weeks
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 30389952

Group type: EXPERIMENTAL
Intervention: Mean SAT thickness measured from eight standardised ultrasound sites
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mean SAT thickness measured from 216 randomly selected sites
Number of subjects: 10
Study: 26643052

Group type: EXPERIMENTAL
Intervention: Home-based constraint-induced therapy (CIT) for 4 weeks
Number of subjects: 23
Study: 24440221

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Long-term infliximab
Number of subjects: 24

Group type: COMPARATOR
Intervention: No infliximab
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infliximab for most of the follow-up period
Number of subjects: 24

Group type: COMPARATOR
Intervention: Infliximab for shorter periods
Number of subjects: 24
Study: 21385196

Group type: EXPERIMENTAL
Intervention: Montelukast for 4-8 weeks
Number of subjects: 252
Study: 20370845

Group type: EXPERIMENTAL
Intervention: Oxycodone prolonged release/naloxone prolonged release
Number of subjects: 379
Study: 17547746

Group type: EXPERIMENTAL
Intervention: Long-acting corticosteroid injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-COPD control group
Number of subjects: 90
Study: 16354439

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 48
Study: 12092034

Group type: EXPERIMENTAL
Intervention: Echinococcus granulosus infection (cystic echinococcosis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinococcus multilocularis infection (alveolar echinococcosis)
Number of subjects: 0
Study: 10539748

Group type: COMPARATOR
Intervention: 0 micromol RE/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5.2 micromol RE/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10.5 micromol RE/d
Number of subjects: 26
Study: 8001370

Group type: COMPARATOR
Intervention: Age group > 80 years
Number of subjects: 774

Group type: COMPARATOR
Intervention: Age group ≤ 45 years
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Patients with good neurologic function
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Independent predictors of good neurologic recovery
Number of subjects: 774
Study: 2339011

Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: TTS-placebo
Number of subjects: 40
Study: 231374

Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH (0.5 mg) for 4 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 4 days
Number of subjects: 32
Study: 31173422

Group type: EXPERIMENTAL
Intervention: Vaccine-and-behaviour-change intervention (VBC)
Number of subjects: 9325

Group type: EXPERIMENTAL
Intervention: Vaccine-only (V)
Number of subjects: 9325

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9325

Group type: EXPERIMENTAL
Intervention: VBC
Number of subjects: 9325

Group type: EXPERIMENTAL
Intervention: V
Number of subjects: 9325
Study: 27885469

Group type: EXPERIMENTAL
Intervention: NEPA (netupitant 300 mg and palonosetron 0.50 mg)
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Oral PALO (palonosetron 0.50 mg)
Number of subjects: 1455
Study: 26008855

Group type: EXPERIMENTAL
Intervention: Hypoxia (simulated altitude of 3,500 m)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normoxia (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (Hypoxia and Normoxia)
Number of subjects: 32
Study: 24063779

Group type: EXPERIMENTAL
Intervention: Cosmetics containing purified bee venom (PBV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cosmetics without purified bee venom (PBV)
Number of subjects: 12
Study: 21725873

Group type: EXPERIMENTAL
Intervention: Pu'er tea extract
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19019046

Group type: EXPERIMENTAL
Intervention: Painful diabetic peripheral neuropathy (DPN)
Number of subjects: 401
Study: 16878063

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (corticoid)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Diclofenac (NSAID)
Number of subjects: 73
Study: 12633482

Group type: EXPERIMENTAL
Intervention: Post-Acute Care (PAC) coordinator
Number of subjects: 598

Group type: COMPARATOR
Intervention: Usual discharge planning (control)
Number of subjects: 598
Study: 10714480

Group type: EXPERIMENTAL
Intervention: BDP-HFA (HFA 134a)
Number of subjects: 229

Group type: COMPARATOR
Intervention: BDP-CFC (CFC)
Number of subjects: 229
Study: 8823470

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus 13‐cis‐retinoic acid (RA) at a dosage of 1 mg/kg/day for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus 13‐cis‐retinoic acid (RA)
Number of subjects: 40
Study: 1396064

Group type: EXPERIMENTAL
Intervention: Tramadol HCL capsule (THC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control drugs (AT-237 and Anfendein)
Number of subjects: 51
Study: 4079660

Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin, administered intranasally, double-blind, prior to ethanol ingestion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo, administered intranasally, double-blind, prior to ethanol ingestion
Number of subjects: 26
Study: 30802313

Group type: EXPERIMENTAL
Intervention: WoTWoD cultural respect framework
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 30204698

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2947

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2947
Study: 26764061

Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard Optimal Care (SOC)
Number of subjects: 500
Study: 25244390

Group type: EXPERIMENTAL
Intervention: Posttreatment motivation (being in action vs. preaction)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Pretreatment motivation
Number of subjects: 392
Study: 22647933

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 345
Study: 22106975

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19195916

Group type: EXPERIMENTAL
Intervention: Imiglucerase infused every 4 weeks (Q4)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Imiglucerase infused every 2 weeks (Q2)
Number of subjects: 95
Study: 17004259

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA-ME)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 495
Study: 12752346

Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Famotidine 1.0 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11069316

Group type: EXPERIMENTAL
Intervention: alendronate 10 mg o.d.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: ASA 650 mg q. d.s.
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo o.d.
Number of subjects: 76
Study: 10225757

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Plasma Exchange followed by Intravenous Immunoglobulin (PE + IVIg)
Number of subjects: 383
Study: 8038352

Group type: EXPERIMENTAL
Intervention: famotidine (20 mg b.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: cimetidine (400 mg b.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg b.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 2902494

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for two years or until death
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 181
Study: 29454393

Group type: EXPERIMENTAL
Intervention: Feedback from an electronic audit and feedback dashboard providing ICU's own performance, median and top 10% peer performance, and improvement recommendations.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Feedback from an electronic audit and feedback dashboard.
Number of subjects: 72
Study: 28111861

Group type: EXPERIMENTAL
Intervention: Menstrual cup (MC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Endocervical swab (ECS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: ECS-enriched cervicovaginal lavage (eCVL)
Number of subjects: 51
Study: 25887362

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss only (D)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss plus exercise (D + E)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Exercise-only control (E)
Number of subjects: 454
Study: 25066942

Group type: EXPERIMENTAL
Intervention: Rusie Dutton
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 50
Study: 22289235

Group type: EXPERIMENTAL
Intervention: Full kinematic chain manual and manipulative therapy (MMT) plus exercise
Number of subjects: 111

Group type: COMPARATOR
Intervention: Targeted hip manual and manipulative therapy (MMT) plus exercise
Number of subjects: 111
Study: 20798154

Group type: EXPERIMENTAL
Intervention: Walking group (exercise program)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nonwalking)
Number of subjects: 22
Study: 19057270

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally until disease progression or intolerable toxicity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 62
Study: 15909433

Group type: EXPERIMENTAL
Intervention: Topical gentamicin
Number of subjects: 0
Study: 12824811

Group type: EXPERIMENTAL
Intervention: Alcohol (0.75 g/kg mixed with diet soda)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (diet soda)
Number of subjects: 20
Study: 10586830

Group type: EXPERIMENTAL
Intervention: Chemoradiation (radiotherapy combined with systemic chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 9376450

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 15
Study: 8013997

Group type: EXPERIMENTAL
Intervention: Autotransfusion program
Number of subjects: 0
Study: 2429622

Group type: EXPERIMENTAL
Intervention: Iron and vitamin C
Number of subjects: 97

Group type: COMPARATOR
Intervention: Vitamin C only (control group)
Number of subjects: 97
Study: 30135032

Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 0
Study: 27543527

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 100
Study: 24801511

Group type: EXPERIMENTAL
Intervention: Visumax laser
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intralase laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study: 22275296

Group type: EXPERIMENTAL
Intervention: SMP enriched with GMP and G600
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lactose powder control
Number of subjects: 120

Group type: COMPARATOR
Intervention: SMP control
Number of subjects: 120
Study: 20628331

Group type: EXPERIMENTAL
Intervention: Score chart for predicting persistent complaints
Number of subjects: 468
Study: 18322633

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 mcg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15731291

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg or 120 mg once a day, Naproxen 500 mg twice daily
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Etoricoxib or Naproxen
Number of subjects: 387
Study: 12438293

Group type: EXPERIMENTAL
Intervention: Parental history of type 2 diabetes
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: eNOS gene polymorphism
Number of subjects: 87
Study: 10876435

Group type: EXPERIMENTAL
Intervention: Bacteriostatic HME (BHME)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonbacteriostatic HME (NHME)
Number of subjects: 99
Study: 7485925

Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg/promethazine 50 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg/placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Phenobarbital 100 mg/promethazine 50 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Phenobarbital 100 mg/placebo
Number of subjects: 304
Study: 8398960

Group type: EXPERIMENTAL
Intervention: 1 mg morphine injected intravenously
Number of subjects: 37

Group type: COMPARATOR
Intervention: 1 ml of physiologic saline diluted to 5 ml with 5% glucose (Control)
Number of subjects: 37
Study: 3803416

Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine (CBZ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29068756

Group type: EXPERIMENTAL
Intervention: HILT+EX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PL+EX
Number of subjects: 100

Group type: COMPARATOR
Intervention: HILT
Number of subjects: 100

Group type: COMPARATOR
Intervention: PL
Number of subjects: 100
Study: 26169871

Group type: EXPERIMENTAL
Intervention: WWB + hiAXOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WWB + AXOS + RS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WWB + hiRS
Number of subjects: 0

Group type: COMPARATOR
Intervention: WWB
Number of subjects: 0